Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HELPBullishCorporate Developmentsnews

Medium materiality6/10

Helus Pharma renames from Cybin as it pivots toward commercial operations.

Oct 1, 2026, 7:49 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Name change and pivot toward commercialization can improve branding, visibility, and future milestone expectations; potential near-term price reaction ahead of regulatory and clinical milestones.

AI summary

What happened, with direct paths to the underlying reporting

Helus Pharma announced its legal name change from Cybin Inc. to Helus Pharma Inc., effective Oct 1, 2026, with shareholder approval on Sept 22, 2026. The update aligns with a shift from clinical-stage work toward commercialization, underpinned by HLP003 in Phase 3 for MDD and HLP004 in Phase 2 for GAD. Branding could influence investor perception and milestones.

Helus Pharma changes name from Cybin to Helus; effective Oct 1, 2026.
Shareholders approved the name change at the Sept 22, 2026 meeting.
Ticker remains HELP; new CUSIP 423492107; ISIN CA4234921076.
HLP003 Phase 3 for MDD; HLP004 Phase 2 for GAD.
Company aims to shift from clinical stage to commercial-ready pharma.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.